West Pharmaceutical adjusts guidance on GLP-1 demand, shares extend 30-day gain

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 14:51.

West Pharmaceutical Services (US9523901012) lifted its full-year 2026 guidance earlier this quarter, citing strong demand linked to GLP-1 therapies, with the stock listed on the NYSE. The company now expects higher adjusted EPS and sales for 2026 compared with its previous outlook, according to recent analyst and market commentary.

What the guidance shows

According to TrendSpider, West Pharmaceutical Services raised its 2026 adjusted EPS guidance from a prior range of $7.85-$8.20 to $8.40-$8.75, above earlier internal assumptions. The same source reports that the company also lifted its full-year 2026 sales guidance from $3.215 billion-$3.275 billion to $3.295 billion-$3.350 billion, topping previous estimates.

MarketBeat notes that for the second quarter 2026 West Pharmaceutical Services issued EPS guidance of $2.05-$2.12, compared with consensus expectations of around $2.00 per share. The company also guided Q2 2026 revenue to $830-$850 million, modestly ahead of the $818.7 million consensus estimate cited by MarketBeat.

Analyst views and sector context

TrendSpider data shows that around 75 percent of analysts covering West Pharmaceutical Services currently rate the shares as a Buy, underscoring a broadly constructive stance on the stock. The same source highlights that the West Pharmaceutical Services stock is up roughly 10.73 percent over the past 30 days, a marked short-term gain against the wider healthcare equipment peer group.

Recent Yahoo Finance commentary suggests that West Pharmaceutical Services could be trading at an implied discount of about 6.9 percent relative to some growth scenarios for GLP-1 related demand, which underpin the containment and delivery solutions business. MarketWatch notes that despite daily gains, the shares have at times underperformed selected competitors, signaling a more cautious positioning among some investors even as absolute performance remains positive.

The business behind the guidance

BCC Research describes West Pharmaceutical Services Inc. as a global manufacturer of containment and delivery solutions for injectable drugs, supplying components such as stoppers, seals and systems used with syringes and vials. The company generated revenue of about $3.074 billion in 2025, reflecting its scale in drug delivery infrastructure across North America and Europe.

Where the shares trade today

TrendSpider lists West Pharmaceutical Services, Inc. shares (US9523901012) at around $346.25 on the NYSE, with the quote updated on June 25, 2026, in US dollars.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. All data are based on sources cited in the text and may change over time; investors should consult original filings and professional advisors before making investment decisions.